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ABSTRACT 
Objective: To investigate if curative prostate cancer (PCa) treatment was received 
less often by men with both PCa and Type 2 diabetes mellitus (T2DM), as little is 
known about if a diagnosis of T2DM influences receipt of curative treatment in men 
with localised PCa.  
Subjects/Patients and methods: Data from Prostate Cancer database Sweden 
(PCBaSe) from men with T2DM and PCa (n=2,210) was used to compare with those 
with PCa only (n=23,071).  All men had intermediate (T1-2, Gleason score 7 and/or 
PSA 10-20 ng/ml) or high risk (T3 and/or Gleason score 8-10 and/or PSA 20—50 
ng/ml) localised PCa diagnosed between 1st January 2006 and 31st December 2014. 
Multivariate logistic regression was used to calculate odds ratios for receiving 
curative treatment in men with and without T2DM.  Overall survival, up to 8 years of 
follow-up, was calculated for men with T2DM only and for men with T2DM and PCa.  
 Results: Men with T2DM were less likely to receive curative treatment for PCa than 
men without T2DM (OR: 0.78, 95%CI: 0.69-0.87). The 8 year overall survival was 
79% and 33% respectively for men with T2DM and high risk PCa who did and did 
not receive curative treatment.   
Conclusions: Men with T2DM were less likely to receive curative treatment for 
localised intermediate and high risk PCa. Men with T2DM and high risk PCa who 
received curative treatment had substantially higher survival than those who did not.  
Some of the survival differences represent a selection bias of the healthiest patients 
to receive curative treatment.  Clinicians need to interpret such data carefully and 
ensure that individual patients with T2DM and PCa are not under nor over treated 
unnecessarily. 
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Introduction  
Prostate cancer (PCa) is the commonest cancer in men in Europe, with around 
417,000 new cases diagnosed in 2012 (1). Incidence is strongly related to age and 
about 36% of cases are diagnosed in men aged 75 or over, with a peak incidence 
between age 75 and 79 (2). There are over 60 million people who have been 
diagnosed with Type 2 Diabetes Mellitus (T2DM) across Europe, and it is estimated 
that over 10% of men in Europe have T2DM (3). As a result, these two increasingly 
prevalent conditions often occur together in the same men. However, the relationship 
is more complex than just two prevalent conditions co-existing.  T2DM is included in 
the cluster of disorders which comprise the metabolic syndrome (MetS)(4). During 
the last decade, studies have investigated whether MetS is involved in the aetiology 
of prostate cancer (5-7).  A meta-analysis to quantify the risk of PCa related to MetS 
found a pooled relative risk of 1.54 (95%CI:1.23-1.94) (4). Recent studies have also 
suggested that the presence of MetS or some of its features is associated with 
higher grade disease in men with prostate cancer and can lead to more rapid 
progression to castrate resistant prostate cancer (8, 9). 
  
 
Men with untreated localised PCa have different life expectancy depending on their 
comorbidity (10).  A Canadian case-cohort study of 630 men studied the impact of 
specific comorbid conditions on death within 10 years in men with localised PCa 
(11). Respiratory and cardiovascular diseases were the most common conditions 
and most strongly associated with an increased risk of death. Pharmacologically-
treated T2DM was present in 7% of the men at the time of PCa diagnosis and was 
associated with a 35% increased risk of death from other causes than PCa at 10 
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years. The association between components of the Charlson Comorbidity Index 
(CCI) on mortality following radical prostatectomy has also been studied.  Eight 
conditions were significant predictors of overall mortality, including diabetes (12). 
Thus, T2DM may be associated with a shorter life expectancy in men with PCa.  
 
As a result of the association between comorbidities and life-expectancy in men with 
localised PCa (10, 12, 13), current PCa treatment guidelines recommend that  a man 
should have a life expectancy of ten years or more in order for curative treatment  to 
be indicated (14).   
 
Given the above we used data from PCBaSe Sweden to investigate if a diagnosis of 
T2DM decreased the probability of curative treatment in men with localised PCa and 
how this was associated with PCa-specific and all-cause mortality. 
 
Subjects/Patients and Methods 
Study population and data collection  
PCBaSe Sweden 3.0 is based on the National Prostate Cancer Register (NPCR) of 
Sweden, which became nationwide in 1998 and covers 98% of all newly diagnosed 
cases of PCa, as compared to the Swedish Cancer Register (15, 16).  NPCR 
includes information on date of diagnosis, age at diagnosis, tumour stage and 
differentiation, serum levels of prostate specific antigen (PSA) at time of diagnosis.   
Risk categories are determined according to a modified version of the National 
Comprehensive Cancer Network Guideline (17) as follows: Low risk: local clinical 
stage T1-2, Gleason score of 2-6 and PSA< 10 ng/ml; intermediate risk: T1-2, 
Gleason score 7 and/or PSA 10-20 ng/ml; high risk: T3 and/or Gleason score 8-10 
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and/or PSA 20—50 ng/ml; regionally metastatic/locally advanced:T4 and/or N1 
and/or PSA 50-100 ng/ml in the absence of distant metastases (M0 or MX); distant 
metastases: M1 and/or PSA > 100 ng/ml. Using the Swedish personal identity 
number, five PCa-free men from the general population in Sweden were randomly 
selected within sets of men who matched the index case on birth year and county of 
residence and included in a PCa-free control cohort (15).  Both men with PCa and 
those in the control cohort were subsequently linked to a series of national health 
care registers and demographic databases, to obtain data on comorbidity, 
socioeconomic status, and cause of death, including the National Diabetes Register 
(NDR). 
 
PCBaSetraject includes all of the data in PCBaSe 3.0, but has additional linkages. It 
focuses specifically on men diagnosed with PCa between 1992 and 2012 with 
available information on their complete treatment trajectory (16). For the current 
study, we included all men diagnosed with intermediate or high risk localised PCa 
(i.e. eligible for radical treatment with either radical prostatectomy (RP) or 
radiotherapy (RT)) between 1st January 2006 and 31st December 2014, to allow use 
of the National Prescribed Drug Register which started on 1st July 2005. The 
Regional Research Ethics Board at Umeå University approved this study.  
 
The main outcome variable for this study, treatment with RP and RT, was retrieved 
from PCBaSetraject, which represents actual treatment received, not just intended 
primary treatment.  We looked only at primary treatment, i.e. first definitive treatment 
received after PCa diagnosis and not subsequent treatments. The main exposure 
variable for this study, T2DM, was defined as receiving two or more consecutive 
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prescriptions for an anti-diabetic drug within 6 months.  Information on filled 
prescriptions of metformin, sulphonylurea and insulin was obtained from The 
National Prescribed Drug Register using ATC codes (insulin- ANA, metformin- 
A10BA/BD, sulphonylurea- A10BB) (18).  Less than 2% of those with T2DM received 
prescriptions for alternative oral hypoglycaemics, in this analysis these were 
considered in the metformin group. We did not exclude those with Type 1 Diabetes 
receiving insulin prescriptions, however, these cases were few. Comorbidities were 
measured by the Charlson Comorbidity Index (CCI), which assigns weights to a 
number of medical conditions, including diabetes and hypertension based on 
discharge diagnoses in the Patient Register (13).  In this analysis we excluded 
diabetes from the CCI score.  Each condition was assigned a score of 1, 2, 3 or 6 
and the final CCI is given as the sum of these scores. Individuals were grouped into 
CCI categories for final scores of 0, 1, 2 or 3+.  Information on age at diagnosis, T-
stage, Gleason score, PSA at diagnosis, proportion of cores with cancer, mode of 
detection of PCa, education and civil status was also used. For men with missing 
data on Gleason score (0.7%), we applied multivariate imputation using chained 
equations (MICE), also known as imputation, using fully conditional specifications 
(19). The MICE method imputes multiple variables sequentially using univariate fully 
conditional specifications.  
 
Analysis 
We used multivariate logistic regression to calculate odds ratios for receiving 
curative treatment in men with and without T2DM (as defined above). The analysis 
was adjusted for age, T stage, Gleason score, proportion of cores with cancer, CCI 
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(excluding diabetes), mode of detection, education and civil status. When adjusting 
for PSA linear splines with knots at 3, 10 and 20 were used. 
 
We then performed an analysis to evaluate how an additional diagnosis of 
hypertension, dyslipidaemia, or cardiovascular disease (CVD) as compared to only 
T2DM affected the association between T2DM and curative treatment.  We used 
ATC codes for the following prescriptions from the Prescribed Drug register to 
assess these additional diagnoses: statins (C10), anti-hypertensive (C02) and anti-
coagulants (B01). 
 
To evaluate the association of PCa and T2DM with survival, we created a 
comparison cohort including men with only T2DM from the PCa- free cohort.  First 
we selected all index cases (PCa and T2DM, as registered with a date of diagnosis 
from the NDR).  Controls in the comparison cohort were matched with these index 
cases on age (+/- 1 year), duration of T2DM and type of T2DM treatment (insulin vs. 
oral drugs). For each index case we selected 5 controls in each comparison cohort. 
Overall survival up to 8 years of follow-up was then calculated for men in the 
comparison cohort and for men with T2DM and PCa who did and did not receive 
curative treatment. 8-year survival probabilities were assessed as data was only 
available for the period 2006-2014. Finally, we calculated the cumulative incidence of 
PCa specific and death from other causes in those who did and did not receive 
curative treatment.  
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All data management was performed with SAS version 9.3 (SAS Institute, Cary, NC) 
and all data analysis was conducted with R version 2.13.2 (R Foundation for 
Statistical Computing, Wien, Austria). 
 
Results  
2,210 men with PCa and T2DM and 23,071 men with PCa only were included in the 
analysis.  Of those with T2DM, 916 were treated with insulin and 1,537 with 
metformin (Table 1).  Men with T2DM were older than those without T2DM; only 6% 
of men with T2DM were under 60 years, compared to 13% of men with no diabetes 
(Table 1).  Men with T2DM also had higher CCI and were more likely to have high 
risk rather than intermediate risk prostate cancer, in comparison to men without 
T2DM (Table 1). Those with T2DM were also more likely to have a Gleason score of 
greater than 8, a higher proportion of cores with cancer and a PSA >20 ng/ml (Table 
1).   
 
Men with both T2DM and PCa were less likely to receive curative treatment for PCa 
than those without T2DM (OR: 0.78; 95%CI: 0.69-0.87) (Table 2). Men with T2DM 
treated with insulin were less likely to receive curative treatment (OR: 0.62; 95%CI: 
0.53-0.74) than men on metformin (OR: 0.91; 95%CI: 0.80-1.04) (Table 2).  
 
Men with other comorbidities (based on additional filled prescriptions for drugs for 
hypertension, dyslipidaemia, or CVD) in addition to T2DM had virtually the same 
probability of curative treatment for PCa; T2DM only (OR: 0.78; 95%CI: 0.69-0.88), 
T2DM and dyslipidaemia (OR: 0.79; 95%CI: 0.69-0.90), and T2DM and CVD (OR: 
0.75; 95%CI: 0.60-0.93) ( Table 3). 
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The 8 year overall survival was lower in PCa-free men with T2DM compared to men 
with T2DM and PCa who received curative treatment. At eight years of follow-up, the 
survival was 73% for men with T2DM and no PCa, 79% for men with T2DM and high 
risk PCa who received curative treatment and 33% for men with T2DM and high risk 
PCa who did not receive curative treatment. (Figure 1). Corresponding numbers for 
intermediate risk PCa were 77%, 86% and 55%.  The cumulative incidence of PCa 
death was low in both intermediate and high risk PCa when curative treatment was 
received. In men with intermediate risk PCa who were not curatively treated, the 
cumulative incidence of PCa death remained low at 8 years whilst the cumulative 
incidence of death from other causes was much higher. However, in those men with 
high risk PCa the cumulative incidence of PCa death contributed to a much greater 
proportion of the overall death in those not treated curatively. (Figure 2).  
 
 
 
 
Discussion  
Men with T2DM were less likely to receive curative treatment for localised PCa, 
particularly those receiving insulin .  While men with T2DM and high risk prostate 
cancer who did receive curative treatment had substantially higher survival 
compared to men with T2DM and PCa who were conservatively treated. 
 
Comorbidities affect 10-year mortality more than PCa-mortality in men with 
conservatively treated localised PCa (10-12), which has led to the recommendation 
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that men should have a 10 year life expectancy or more  in order for a  curative 
treatment to be indicated (14). However, it is difficult to predict an individual’s 10 year 
life expectancy and none of the existing nomograms, which help calculate this, are 
not currently widely used in clinical practice (20).   
The impact of comorbidity and age on treatment and survival of men with PCa has 
been investigated in a Dutch study of over 6000 men (21). The proportion of men 
aged 60–69 years who underwent RP decreased significantly from 32% of men 
without comorbidity to 17% of men with two or more comorbid conditions.  This 
proportion decreased further from 8% to 3% in those aged 70–79 years.  A previous 
study using data from PCBaSe demonstrated that as CCI score increased , men 
were more likely to receive RT than RP (22). Our study findings are in line with these 
observations even after taking into account a wide range of potential confounders 
(age, comorbidities and cancer characteristics).  
 
However, to interpret our findings, it is important to evaluate life expectancy as 
outlined in the guidelines for PCa treatment (14). The  life expectancy of a Swedish 
man at age 65 is 19 years (23), with similar figures seen across Europe(23). T2DM 
decreases life expectancy by up to 10 years (24).  However, men with PCa and 
T2DM who received curative treatment in our study had a substantially higher overall 
survival than men with T2DM and PCa who received conservative treatment The 
selection of the healthiest men and allocation to curative treatment among men with 
T2DM and PCa was indicated by the fact that these men had a better overall survival 
than corresponding PCa-free men with T2DM (Figure 1).  The selection of healthy 
men for curative treatment is also highlighted by the lower 90-day mortality after RP 
compared with the background population in a previous Swedish study (25). This 
 12 
selection is also seen here in PCa mortality (Figure 2), which remained low 
regardless of PCa treatment for intermediate risk disease.  The higher proportion of 
death from other causes in men not curatively treated confirms that these men have 
high co-morbidity with ensuing increased risk of death from competing causes. 
However, in men with conservatively treated high risk PCa, 22% died of PCa within 8 
years of diagnosis, suggesting that a larger proportion of these men should have 
received curative treatment. We also show here (Table 1) that men with T2DM were 
more likely to receive primary ADT than those without T2DM (25% Vs.15%). Given 
the metabolic and cardiovascular side effects of ADT, this is another reason to 
ensure that men with PCa and T2DM are not undertreated with respect to curative 
treatment. 
 
Strengths of our study are its large size, the population-based design and the 
comparison cohort of PCa-free men with T2DM. Furthermore, we had access to data 
from a number of nationwide population-based high-quality registers including The 
Prescribed Drug Register, The Inpatient Register, The Cause of Death Register and 
The National Diabetes Register. Limitations include that we only had 8 years of 
follow-up instead of the conventional 10 year survival curves or estimated life 
expectancies.  A further limitation is that by using drug prescriptions as a proxy for 
T2DM, we have missed all T2DM cases treated by diet alone. However, diet 
controlled T2DM is unlikely to have influenced PCa treatment decisions. We show 
that in fact, it is only those treated with insulin who are less likely to receive curative 
treatment. As discussed above we acknowledge that a selection bias of the 
healthiest men to receive curative treatment among men with T2DM and PCa exists. 
This was indicated by the fact that these men had a better overall survival than 
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corresponding PCa-free men with T2DM. There may also be confounding by 
indication which influenced those receiving curative treatment i.e. those with the 
most favourable prognosis may have preferentially been chosen for curative 
treatment. However, by adjusting for tumour characteristics we have accounted for 
this in our analysis. 
 
 
Conclusion 
Men with T2DM were less likely to receive curative treatment for localised PCa.  
Those men with T2DM and high risk prostate cancer who received curative 
treatment had substantially higher survival compared to men with T2DM and PCa 
who were conservatively treated. Some of the survival differences represent a 
selection bias of the healthiest patients to receive curative treatment.  However, in 
men with conservatively treated high risk PCa, 22% died specifically of PCa, 
suggesting that a larger proportion of these men should have received curative 
treatment. Clinicians need to interpret such data carefully and ensure that individual 
patients with T2DM and PCa are not under nor over treated unnecessarily.  
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Tables 
Table 1: Patient characteristics by diabetes status and diabetes treatment in Prostate 
Cancer database Sweden (PCBaSe)   
 
No diabetes  % T2DM1 (all) % Insulin % Metformin  %  
n= 23071 
 
n= 2210 
 
n= 916 
 
n= 1537 
 
Age at PCa diagnosis 
        
 
67.9 
 
70 
 
70.1 
 
69.6 
 
Age, years 
        
<60 3016 13.1 134 6.1 55 6.0 94 6.1 
60-64 4593 19.9 312 14.1 117 12.8 235 15.3 
65-69 6184 26.8 611 27.6 266 29.0 451 29.3 
70-74 5277 22.9 603 27.3 246 26.9 422 27.5 
75-80 4001 17.3 550 24.9 232 25.3 335 21.8          
Year of PCa diagnosis 
        
2006-2008 7843 34.0 672 30.4 276 30.1 441 28.7 
2009-2010 8006 34.7 751 34.0 321 35.0 511 33.2 
2011-2012 7222 31.3 787 35.6 319 34.8 585 38.1          
CCI2 
        
0 18985 82.3 1512 68.4 558 60.9 1116 72.6 
1 2428 10.5 383 17.3 183 20.0 245 15.9 
2 1187 5.1 190 8.6 89 9.7 118 7.7 
 3+ 471 2.0 125 5.7 86 9.4 58 3.8          
Risk category3 
        
 Intermediate risk 14503 62.9 1187 53.7 468 51.1 825 53.7 
 High risk 8568 37.1 1023 46.3 448 48.9 712 46.3          
Educational level 
        
Low 7897 34.2 919 41.6 391 42.7 631 41.1 
Middle 9091 39.4 854 38.6 355 38.8 597 38.8 
High 5933 25.7 417 18.9 164 17.9 295 19.2 
Missing 150 0.7 20 0.9 6 0.7 14 0.9          
Civil status  
        
Not married 7241 31.4 779 35.2 332 36.2 551 35.8 
Married 15830 68.6 1431 64.8 584 63.8 986 64.2          
Gleason Score  
        
GS 2-6 4913 21.3 387 17.5 181 19.8 261 17.0 
GS 7 (3+4) 9471 41.1 802 36.3 301 32.9 561 36.5 
GS 7 (4+3) 4378 19.0 458 20.7 191 20.9 307 20.0 
GS 7 UNS 162 0.7 14 0.6 4 0.4 10 0.7 
GS 8 2627 11.4 334 15.1 143 15.6 238 15.5 
GS 9-10 1520 6.6 215 9.7 96 10.5 160 10.4 
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1Type 2 Diabetes 
2Charlson Co-morbidity Index 
3Risk groups according to modification of the National Comprehensive Cancer Network Practice 
Guidelines(17) 
4 Androgen deprivation therapy   
         
Percentage cores 
positive for cancer 
        
0-33% 8767 43.5 779 40.3 321 40.4 531 39.1 
33-66% 7043 35.0 650 33.6 267 33.6 467 34.4 
66-100% 4335 21.5 505 26.1 206 25.9 360 26.5          
Serum PSA (ng/ml) 
        
0-3 418 1.9 52 2.5 23 2.6 32 2.2 
3-10 10112 46.0 909 43.0 336 38.5 661 45.1 
10-20 7605 34.6 706 33.4 313 35.9 478 32.6 
20-50 3837 17.5 446 21.1 201 23.0 295 20.1 
         
Primary Treatment          
ADT4  3552 15.4 560 25.3 276 30.1 336 21.9 
Radical Prostatectomy 9057 39.3 501 22.7 182 19.9 377 24.5 
Radiotherapy  6343 27.5 687 31.1 257 28.1 524 34.1 
Watchful Waiting  4119 17.9 462 20.9 201 21.9 300 19.5 
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Table 2: Odds ratios and 95% confidence intervals of curative treatment by diabetes status.    
  
All  men 
with 
diabetes 
 
Insulin 
T2DM 
 
Metformin 
T2DM 
 
Model 
      
 
OR 95%CI OR 95%CI OR 95%CI 
Diabetes 0.58 ( 0.53 - 0.63 ) 0.47 ( 0.41 - 0.53 ) 0.73 ( 0.66 - 0.81 ) 
+ Age  0.73 ( 0.66 - 0.81 ) 0.55 ( 0.47 - 0.65 ) 0.87 ( 0.77 - 0.99 ) 
 +CCI1 0.78 ( 0.70 - 0.86 ) 0.62 ( 0.53 - 0.72 ) 0.91 ( 0.81 - 1.03 ) 
 +T Stage 0.79 ( 0.71 - 0.88 ) 0.62 ( 0.53 - 0.73 ) 0.93 ( 0.82 - 1.05 ) 
 +Gleason 0.75 ( 0.67 - 0.83 ) 0.60 ( 0.51 - 0.71 ) 0.88 ( 0.77 - 0.99 ) 
+PSA2 0.75 ( 0.67 - 0.83 ) 0.61 ( 0.51 - 0.71 ) 0.88 ( 0.77 - 1.00 ) 
+% positive cores 0.74 ( 0.66 - 0.83 ) 0.59 ( 0.50 - 0.70 ) 0.87 ( 0.77 - 0.99 ) 
+mode of 
detection 
0.76 ( 0.68 - 0.84 ) 0.61 ( 0.51 - 0.72 ) 0.88 ( 0.78 - 1.01 ) 
+Education 0.77 ( 0.69 - 0.86 ) 0.62 ( 0.52 - 0.73 ) 0.90 ( 0.79 - 1.02 ) 
+Civil Status 0.78 ( 0.69 - 0.87 ) 0.62 ( 0.53 - 0.74 ) 0.91 ( 0.80 - 1.04 ) 
 
Crude model is followed by multivariate models with increasing number of factors included as adjustment 
 
1Calculated excluding diabetes  
2For PSA linear splines with knots at 3, 10 and 20 were used 
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Table 3: Odds ratios and 95% confidence intervals of curative treatment in men with 
diabetes and additional comorbidities compared to those with T2DM only.  
  
DM  and 
hypertension3  
 
DM and high 
cholesterol3 
 
DM and 
CVD3 
 
Model OR CI OR CI 
  
       
Crude 0.54 ( 0.49 - 0.60 ) 0.58 ( 0.52 - 0.65 ) 0.48 ( 0.40 - 0.57 ) 
 Age  0.73 ( 0.65 - 0.81 ) 0.73 ( 0.65 - 0.83 ) 0.66 ( 0.54 - 0.81 ) 
 CCI1 0.79 ( 0.70 - 0.88 ) 0.80 ( 0.71 - 0.91 ) 0.79 ( 0.64 - 0.97 ) 
 T Stage 0.80 ( 0.71 - 0.90 ) 0.81 ( 0.71 - 0.93 ) 0.80 ( 0.65 - 0.98 ) 
 Gleason 0.75 ( 0.67 - 0.85 ) 0.77 ( 0.67 - 0.88 ) 0.75 ( 0.60 - 0.92 ) 
PSA2 0.76 ( 0.68 - 0.85 ) 0.77 ( 0.67 - 0.88 ) 0.75 ( 0.61 - 0.93 ) 
% positive cores 0.75 ( 0.66 - 0.84 ) 0.76 ( 0.66 - 0.87 ) 0.72 ( 0.58 - 0.89 ) 
mode of detection 0.76 ( 0.68 - 0.86 ) 0.77 ( 0.68 - 0.89 ) 0.74 ( 0.59 - 0.92 ) 
Education 0.77 ( 0.68 - 0.87 ) 0.79 ( 0.68 - 0.90 ) 0.75 ( 0.60 - 0.93 ) 
Civil Status 0.78 ( 0.69 - 0.88 ) 0.79 ( 0.69 - 0.90 ) 0.75 ( 0.60 - 0.93 ) 
 
The ORs are taken from a multivariate model including all covariates listed 
 
1Calculated excluding diabetes 
2For PSA linear splines with knots at 3, 10 and 20 were used 
3Cardiovascular disease, hypertension and high cholesterol were defined by filled prescriptions drugs for these 
conditions in the Prescribed Drug Register 
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